MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

BioCryst Pharmaceuticals Inc

Closed

SectorHealthcare

8.92 -0.89

Overview

Share price change

24h

Current

Min

8.87

Max

8.94

Key metrics

By Trading Economics

Income

27M

32K

Sales

14M

146M

EPS

0

Profit margin

0.022

Employees

580

EBITDA

22M

21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+87.36% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

23M

1.9B

Previous open

9.81

Previous close

8.92

News Sentiment

By Acuity

50%

50%

113 / 375 Healthcare

BioCryst Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Jul 2025, 23:55 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 Jul 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

South32 Expects to Complete Transaction in Late 2025

6 Jul 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 Jul 2025, 22:34 UTC

Acquisitions, Mergers, Takeovers

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 Jul 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 Jul 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 Jul 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 Jul 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 Jul 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Received All Required Authorizations

4 Jul 2025, 15:48 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 Jul 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 Jul 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 Jul 2025, 14:30 UTC

Acquisitions, Mergers, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 Jul 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 Jul 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 Jul 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 Jul 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Peer Comparison

Price change

BioCryst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

87.36% upside

12 Months Forecast

Average 16.75 USD  87.36%

High 30 USD

Low 11 USD

Based on 12 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Sentiment

By Acuity

113 / 375 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.